Shares of Dr.Reddy’s Laboratories Ltd (NYSE:RDY) have received a consensus rating of “Buy” from the eleven analysts that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $39.50.

Several analysts recently commented on RDY shares. Nomura Instinet reiterated a “buy” rating on shares of Dr.Reddy’s Laboratories in a research report on Tuesday, April 21st. ValuEngine upgraded shares of Dr.Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, March 13th. Finally, TheStreet downgraded shares of Dr.Reddy’s Laboratories from a “b” rating to a “c” rating in a research report on Monday, January 27th.

RDY stock opened at $49.66 on Thursday. The company has a fifty day moving average price of $47.77 and a 200 day moving average price of $42.77. Dr.Reddy’s Laboratories has a 12 month low of $33.33 and a 12 month high of $53.64. The company has a market cap of $8.22 billion, a price-to-earnings ratio of 35.22 and a beta of 0.48. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.81 and a quick ratio of 1.23.

A number of institutional investors have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of Dr.Reddy’s Laboratories by 1,719.4% in the 1st quarter. CWM LLC now owns 1,128 shares of the company’s stock valued at $45,000 after purchasing an additional 1,066 shares in the last quarter. Bartlett & Co. LLC purchased a new position in shares of Dr.Reddy’s Laboratories in the 1st quarter valued at about $47,000. Assetmark Inc. increased its holdings in shares of Dr.Reddy’s Laboratories by 1,226.5% in the 4th quarter. Assetmark Inc. now owns 1,499 shares of the company’s stock valued at $61,000 after purchasing an additional 1,386 shares in the last quarter. Cornerstone Advisors Inc. increased its holdings in shares of Dr.Reddy’s Laboratories by 54.5% in the 1st quarter. Cornerstone Advisors Inc. now owns 1,896 shares of the company’s stock valued at $76,000 after purchasing an additional 669 shares in the last quarter. Finally, Banque Cantonale Vaudoise purchased a new position in shares of Dr.Reddy’s Laboratories in the 4th quarter valued at about $90,000. Institutional investors own 12.93% of the company’s stock.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Further Reading: Most Volatile Stocks

Analyst Recommendations for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.